N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=132 Anticoagulation Therapy in the Very Old
Atrial Fibrillation
Primary: Number of Patients Experiencing Stroke — 2; 2; 0 Participants
Phase 2 N=14 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
N/A N=333,664 Anticoagulant Utilization Pattern
Atrial Fibrillation
Primary: Description of the Characteristics of Anticoagulant Initiators — 3.41; 4.30; 3.59; 3.82 Scores on a scale
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
N/A N=26 Strategies for Anticoagulation During Venovenous ECMO
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
N/A N=73,989 Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
N/A N=25 Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
Phase 4 N=66 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Atrial Fibrillation
Primary: Coronary Artery Calcium (CAC) Score — 66; 31 units on a scale
N/A N=341 Anticoagulation With Enhanced Gastrointestinal Safety
Upper Gastrointestinal Bleeding · Peptic Ulcer Hemorrhage · Anticoagulant-induced Bleeding
Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001
Phase 2 N=349 Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
Fibrillation, Atrial
Primary: Number of Participants With at Least One Event of Cerebral Neurologic Event, Systemic Thromboembolism, Death From Any Cause, and/or Major Bleeding Until the End of…
N/A N=63 Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
N/A N=977 Randomized On-X Anticoagulation Trial
Heart Valve Disease
Primary: Thromboembolism — 4.86; 0.29; 2.43; 1.74 %/patient years
N/A N=12 Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days
Phase 4 N=101 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Dementia · Cognition Disorders · Cerebral Ischemic Events
Primary: Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist — 0; 0 Participants
Phase 3 N=1,884 Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
Arterial Thromboembolic Events · Atrial Fibrillation
Primary: Number of Arterial Thromboembolic Events — 2; 3; 2; 0 Arterial thromboembolic events
Phase 4 N=110 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Atherosclerosis
Primary: Coronary Artery Calcium (Serial Calcium Scans) — 26.3; 40.5 mm cubed
Phase 2 N=40 Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Phase 2 N=200 Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
N/A N=109 Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
Atrial Fibrillation
Primary: CHA2-DS2-VASc Score at Baseline — 4.6; 4.3 Units on a scale
N/A N=535 Health-related Quality of Life in Patients on Anticoagulants
Atrial Fibrillation
Primary: Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire — 4.9; 3.6; 4.3; 3.6 Unit on scale
N/A N=160 Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
Atrial Fibrillation · Medication Adherence
Primary: Medication Adherence — 93.08; 89.52 percentage of doses recorded as taken — p=0.28
Phase 4 N=94 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
COVID-19 · Venous Thromboses · Arterial Thrombosis
Primary: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU — 28; 31 Participants
Phase 4 N=100 Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Coronary Artery Disease
Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes
N/A N=103,101 Anticoagulants Comparative Benefit-risk Ratio in Real Life
Atrial Fibrillation
Primary: Clinically Relevant Bleeding — 367; 668; 635; 767 participants with event — p=<0.0001
N/A N=5,982 Comparative Effectiveness of Oral Anticoagulants
Atrial Fibrillation
Primary: Incidence Rate of Stroke — 29.09; 31.59 events per 1000 person years
Phase 2 N=44 Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Inflammation · Coagulation · HIV Infection
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months. — -0.02; 0.09 ln-pg/mL — p=0.26
Phase 3 N=18,201 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period — 159; 173…